ANN ARBOR, May 08, 2013 (GLOBE NEWSWIRE via COMTEX) -- Aastrom Biosciences, Inc. (NASDAQ:ASTM) , the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today ...
Aastrom Biosciences Inc (NASDAQ:ASTM) fell 10.87% at $0.615 after trading 771,408 shares. The company is the leader in developing patient-specific, expanded multicellular therapies for use in the treatment of patients with severe, chronic ...
Aastrom Biosciences logo Zacks reaffirmed their neutral rating on shares of Aastrom Biosciences (NASDAQ: ASTM) in a research note released on Thursday morning, Stock Ratings Network reports.
The big loser recently was Aastrom Biosciences, Inc. (ASTM). In March ASTM shares lost 50% after the company said that it will stop enrollment in and end the Phase 3 Revive clinical trial for patients with critical limb ischemia, or restricted blood ...
He had been president and CEO of Ann Arbor-based Aastrom Biosciences Inc. (Nasdaq: ASTM). While at Aastrom, Mayleben raised $75 million in equity capital and got several of its stem-cell therapies into ongoing FDA trials.
StemCells Inc (NASDAQ:STEM) fell -2.11% to settle at $1.86, Aastrom Biosciences Inc (NASDAQ:ASTM) moved up +7.14% to end at $0.600 while Charles River Laboratories (NYSE:CRL) jumped +1.35% to finish at $44.31 on Tuesday.
As such, I trimmed the roster down to only one company, Osiris Therapeutics, Inc. That said, I believe OSIR is simply the "best of the worst", and is still hampered by the many problems inherent in the sector.
Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. To see all exchange delays, please see disclaimer.